Leonidas Mavroeidis

Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition

Leonidas Mavroeidis, Helen Sheldon, Evangelos Briasoulis et al. · International Journal of Oncology · 2015 · 39 citations · Full text

Medicine, Oncology, Pharmacology +13

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells

Eirini Biziota, Evangelos Briasoulis, Leonidas Mavroeidis et al. · Anti-Cancer Drugs · 2015 · 33 citations · Full text

Medicine, Oncology, Pharmacology +12

Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece

Leonidas Mavroeidis, Vassiliki Metaxa‐Mariatou, Alexandra Papoudou‐Bai et al. · ESMO Open · 2018 · 33 citations · Full text

Medicine, Genetics, Oncology +17

Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab

George Pentheroudakis, Leonidas Mavroeidis, Kyriaki Papadopoulou et al. · Clinical Colorectal Cancer · 2019 · 25 citations

Medicine, Molecular Medicine, Oncology +17

Old drug, new clinical use, no man’s land for the indication: an awareness call from European experts

Stefan Rauh, Leonidas Mavroeidis, Panagiotis Ntellas et al. · ESMO Open · 2020 · 12 citations · Full text

Pharmacy, Health Law, Pharmaceutical Policy +15